Method Development for the Chromatographic Separation of Synthetic Cyclic Peptides and Impurities Utilizing a Systematic Protocol and MaxPeak High Performance Surface Technology

Importance of the Topic

Advanced chromatographic separation of cyclic peptides and their impurities is essential for reliable therapeutic development and quality control. Cyclic peptide antibiotics resist proteolytic degradation and exhibit strong target binding, making them valuable in combating resistant bacterial strains. High-performance separation methods accelerate development and ensure consistent drug purity.

Objectives and Study Overview

This study applied a standardized Waters MaxPeak™ Premier protocol to develop reversed-phase LC methods for five cyclic antibiotic peptides (oritavancin, dalbavancin, caspofungin, daptomycin, anidulafungin) and to resolve dalbavancin from its known impurities. The aim was to demonstrate improved performance using MaxPeak High Performance Surface (HPS) technology compared to traditional stainless-steel hardware.

Methodology and Instrumentation

A systematic Analytical Quality by Design (AQbD)-based workflow guided method screening, risk assessment, and gradient optimization. Key instrumentation and materials:

• LC system: Waters Arc Premier QSM-r with column manager
• Detector: PDA 2998 at 214 nm and QDa™ Mass Detector for peak confirmation
• Software: Empower 3.6.2 for data handling
• Columns: XSelect™ Premier Peptide CSH C18 (2.5 µm, 4.6×150 mm) and XBridge Premier Peptide BEH C18
• Mobile phases: 0.1% formic acid or 0.1% TFA in water and acetonitrile
• Sample preparation: 100% DMSO at 0.1 mg/mL to ensure stability

Key Results and Discussion

Initial screening identified the XSelect Premier column with formic acid additives as providing the best selectivity and peak shape. A gradient shift from 0.5–55% to 10–70% acetonitrile allowed earlier elution and eliminated strong solvent effects, enabling use of 100% DMSO sample solvent. Comparisons on Arc Premier HPS versus traditional stainless-steel systems showed:

• Up to 62% increase in peak area and 67% in peak height
• 35% reduction in tailing factor
• Up to 9% lower RSD in peak area across replicates

Method modifications achieved baseline separation of all five cyclic peptides. For dalbavancin impurity analysis, optimized gradient and 80 °C column temperature allowed resolution of nine structurally related impurities from the main B0 compound.

Benefits and Practical Applications

• Reduced development time through a structured protocol
• Enhanced reproducibility and peak performance using MaxPeak HPS
• Robust impurity monitoring for regulatory compliance
• Facilitated peak identification with QDa mass detection

Future Trends and Potential Applications

Integration of AQbD and automated screening will further streamline peptide method development. Emerging surface technologies and hyphenated detection methods (e.g., high-resolution MS) promise greater throughput and sensitivity. The approach may extend to larger peptides, peptide conjugates, and other challenging biomolecules.

Conclusion

The Waters MaxPeak Premier protocol combined with HPS technology and systematic method development enabled reliable, high-performance separation of cyclic peptide antibiotics and dalbavancin impurities. This approach offers significant advantages in speed, reproducibility, and chromatographic quality over conventional systems.

References

1. Waters MaxPeak™ Premier Peptide Reversed-Phase Columns and Method Screening Kit User Guide, 2023.
2. Van Bambeke F. Drugs 2015;75:2073–2095. DOI:10.1007/s40265-015-0505-8.
3. Xiao P, Pei D. J Med Chem 2007;50(13):3132–3137. DOI:10.1021/jm070282e.
4. Werth BJ et al. Clin Microbiol Infect. 2018 Apr;24(4):429. DOI:10.1016/j.cmi.2017.07.028.
5. World Health Organization. World Health Statistics 2023. WHO, 2023.
6. Scheinfeld N. Dermatol Online J. 2006;12(4). DOI:10.5070/D30wn7d4q9.